EGFR and non-small cell lung carcinoma: With the increasing improvement in molecular science, many NSCLC driver genes, including epidermal growth factor receptor (EGFR), EML4-ALK fusion, ROS1, RET, and MET, have been recognized and have responded to new target therapies in this decade [2].